Mushroom compound targets kidney cancer in dialysis patients

NCT ID NCT05287945

Recruiting now Disease control Sponsor: Oncorena AB Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This early-stage trial is testing a drug called orellanine, derived from a mushroom, in 75 people with advanced kidney cancer who are also on dialysis. The drug is given intravenously to see if it is safe and can shrink tumors. All participants have end-stage kidney disease and have exhausted standard treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Orellanine (a substance from a mushroom, given intravenously)
What this could lead to: If it works, this could point toward a new treatment option for advanced kidney cancer patients who have no other standard therapies available.
What could go wrong: This is an early phase I/II trial with only 75 participants, so the drug may not be effective or could cause serious side effects. It is only tested in patients with end-stage kidney disease on dialysis, so results may not apply to others.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, RENAL CELL are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease clear cell renal carcinoma kidney cancer Neoplasm Metastasis papillary renal cell carcinoma renal cell adenocarcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, RENAL CELL

Contacts and locations

Locations

Clinica Mi Nova Alianca
RECRUITING

Lleida, 25004, Spain
Institut de Cancerologie Gustave-Roussy
NOT_YET_RECRUITING

Villejuif, 94805, France
Karolinska University Hospital
RECRUITING

Stockholm, Sweden
START Lisbon - Hospital de Santa Maria Av
RECRUITING

Lisbon, 1649-035, Portugal
Stanford
RECRUITING

Palo Alto, California, 94304, United States
University of California Irvine
RECRUITING

Orange, California, 92868, United States
University of California San Francisco
RECRUITING

San Francisco, California, 94158, United States
University of Texas - MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
Washington University in St. Louis
RECRUITING

St Louis, Missouri, 63130, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.